Celsion Corporation Announces Oral Presentation at International Vaccines Congress
October 12 2021 - 9:00AM
Celsion Corporation (NASDAQ: CLSN), a clinical-stage development
company focused on DNA mediated immunotherapy and next-generation
nucleic vaccines, announces that Khursheed Anwer, Ph.D., executive
vice president and chief science officer, will be presenting at the
International Vaccines Congress being held virtually October 18-20,
2021. Dr. Anwer’s presentation is titled “Immunogenicity of DNA
Vaccines based on Multicistronic Vectors and Synthetic DNA Delivery
Systems.” The date and time of the presentation will be announced
following publication of the conference agenda.
Dr. Anwer will be discussing ongoing
proof-of-concept studies in SARS-CoV-2 with the Company’s DNA-based
vaccine approach utilizing its PLACCINE platform. PLACCINE,
Celsion’s proprietary design for DNA vectors, encompasses molecular
elements designed to improve the immune response by targeting
multiple antigens of a pathogen or multiple mutants of the same
antigen. Dr. Anwer will review the PLACCINE technology and the
production of a family of DNA vaccine vectors expressing one or
more SARS-CoV-2 surface antigens as a proof-of-concept target,
verified vector composition and demonstrated expression of the
encoded genes.
“The International Vaccines Congress is an ideal
forum to discuss our ongoing work with unique approaches to
DNA-based vaccines.We view their acceptance of Dr. Anwer’s abstract
as support for our scientific rigor and the promise of our work,”
said Michael H. Tardugno, chairman, president and chief executive
officer of Celsion. “We previously reported that immunization of
Balb-C mice with a plasmid expressing the Spike protein of
SARS-CoV-2 resulted in the production of IgG antibodies with
evidence of viral neutralization and cytotoxic T-cell response
specific to the antigen. We look forward to reporting this and
additional data as we continue to make excellent progress with our
PLACCINE platform.”
About the PLACCINE
Platform
PLACCINE is Celsion’s proprietary plasmid and
DNA delivery technology and the subject of a provisional patent
application that covers a broad range of next-generation DNA
vaccines. An adaptation of the Company’s TheraPlas technology,
PLACCINE is a DNA vaccine technology platform characterized by a
single plasmid DNA with multiple coding regions. The plasmid vector
is designed to express multiple pathogen antigens along with a
potent immune modifier. It is delivered via a synthetic delivery
system and has the potential to be easily modified to create
vaccines against a multitude of infectious diseases,
addressing:
- Viral Mutations:
PLACCINE may offer broad-spectrum and mutational resistance
(variants) by targeting multiple antigens on a single plasmid
vector.
- Enhanced Efficacy:
The potent immune modifiers such as cytokines and chemokines may
improve humoral and cellular responses to viral antigens and can be
incorporated in the plasmid.
- Durable Efficacy:
PLACCINE delivers a DNA plasmid-based antigen that can result in
durable antigen exposure and a robust vaccine response to viral
antigens.
- Storage &
Distribution: PLACCINE allows for stability that is
compatible with manageable vaccine storage and distribution.
- Dosing &
Administration: PLACCINE is a synthetic delivery system
that should require a simple injection that does not require
viruses or special equipment to deliver its payload.
About Celsion
Corporation
Celsion is a fully integrated, clinical stage
biotechnology company focused on advancing a portfolio of
innovative cancer treatments, including immunotherapies, DNA-based
therapies and directed chemotherapies through clinical trials and
eventual commercialization. The company’s product pipeline includes
GEN-1, a DNA-based immunotherapy for the localized treatment of
ovarian cancer. Celsion also has two feasibility stage platform
technologies for the development of novel nucleic acid-based
immunotherapies and other anti-cancer DNA or RNA therapies. Both
are novel synthetic, non-viral vectors with demonstrated capability
in nucleic acid cellular transfection. For more information on
Celsion, visit www.celsion.com.
Forward-looking Statements
Forward-looking statements in this news release
are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based upon current beliefs, expectation, and assumptions and
include statements regarding the platform having the potential to
provide broad protection against coronavirus disease 2019
(COVID-19), and possible future mutations of SARS-CoV-2 or other
coronaviruses. These statements are subject to a number of risks
and uncertainties, many of which are difficult to predict,
including the ability of the Company’s platform to provide broad
protection against COVID-19, and possible future mutations of
SARS-CoV-2 or other coronaviruses, the issuance of a patent to the
Company for use of its technology platform for treating or
preventing infection with the SARS-CoV-2 virus that causes
COVID-19, unforeseen changes in the course of research and
development activities and in clinical trials; the uncertainties of
and difficulties in analyzing interim clinical data, particularly
in small subgroups that are not statistically significant; FDA and
regulatory uncertainties and risks; the significant expense, time
and risk of failure of conducting clinical trials; the need for
Celsion to evaluate its future development plans; possible
acquisitions or licenses of other technologies, assets or
businesses; possible actions by customers, suppliers, competitors
or regulatory authorities; and other risks detailed from time to
time in the Celsion's periodic filings with the Securities and
Exchange Commission. Celsion assumes no obligation to update or
supplement forward-looking statements that become untrue because of
subsequent events, new information or otherwise.
CONTACTS:
Celsion CorporationJeffrey W.
ChurchExecutive Vice President and
CFO609-482-2455jchurch@celsion.com
LHA Investor RelationsKim
Sutton Golodetz 212-838-3777kgolodetz@lhai.com
# # #
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celsion (NASDAQ:CLSN)
Historical Stock Chart
From Apr 2023 to Apr 2024